Navigation Links
Is magnetic therapy effective for tinnitus?
Date:9/18/2012

MAYWOOD, Il. - Loyola University Medical Center is studying whether a new form of non-invasive magnetic therapy can help people who suffer debilitating tinnitus (ringing in the ears).

The therapy, transcranial magnetic stimulation (TMS), sends short pulses of magnetic fields to the brain. TMS has been approved since 2009 for patients who have major depression and have failed at least one antidepressant.

The Loyola study will include patients who suffer from both depression and tinnitus. Recent studies have found that about 12 percent of people with chronic tinnitus also suffer depression and anxiety -- a rate three times higher than that of the general population.

Tinnitus is the perception of sound in one or both ears when there is no external source. It can include ringing, hissing, roaring, whistling, chirping or clicking. About 50 million Americans have at least some tinnitus; 16 million seek medical attention and about 2 million are seriously debilitated, according to the American Tinnitus Association. There is no cure.

The perception of phantom sounds can be more pronounced in people who are depressed. Moreover, antidepressant medications can cause tinnitus occasionally, said Dr. Murali Rao, principal investigator of Loyola's TMS tinnitus study.

Several earlier studies have found that TMS can benefit tinnitus patients. Loyola's study is the first to examine patients who suffer from both tinnitus and depression. "The combination of these two conditions can be extremely debilitating," Rao said.

During TMS treatment, the patient reclines in a comfortable padded chair. A magnetic coil, placed next to the left side of the head, sends short pulses of magnetic fields to the surface of the brain. This produces currents that stimulate brain cells. The currents, in turn, affect mood-regulatory circuits deeper in the brain. The resulting changes in the brain appear to be beneficial to patients who suffer depression. Each treatment lasts 35 to 40 minutes.

The study will enroll 10 to 15 patients. Each patient will receive five treatments a week for four to six weeks, for a total of 20 to 30 treatments. Each patient will be evaluated by a physician three times during the treatment course, or more frequently if the doctor deems necessary.

The treatments do not require anesthesia or sedation. Afterward, a patient can immediately resume normal activities, including driving. Studies have found that patients do not experience memory loss or seizures. Side effects include mild headache or tingling in the scalp, which can be treated with Tylenol.

Rao is chair of the Department of Psychiatry and Behavioral Neurosciences of Loyola University Chicago Stritch School of Medicine. His co-investigator in the study is Sam Marzo, MD, medical director of Loyola's Balance and Hearing Center. Other investigators are Matthew Niedzwiecki, MD, a psychiatry resident; and James Sinacore, PhD, a statistician.


'/>"/>

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

Related medicine news :

1. New research confirms efficacy of transcranial magnetic stimulation for depression
2. In-utero exposure to magnetic fields associated with increased risk of obesity in childhood
3. KRAS gene mutation and amplification status affects sensitivity to antifolate therapy
4. Antibody therapy prevents gastrointestinal damage following radiation exposure in mice
5. Chemotherapy proves life-saving for some leukemia patients who fail induction therapy
6. Immunotherapy for elderly cancer patients finds new promise in drug combination
7. Therapy exploits addiction of leukemia cells
8. Intensity Modulated Radiation Therapy optimal for localized prostate cancer
9. Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
10. Study Casts Doubt on Value of Pricey Prostate Cancer Therapy
11. 19th century therapy for Parkinsons disease may help patients today
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... FOR INFORMATION: ... AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This conference is the ... perioperative nurses in attendance to study the latest evidence-based recommendations and resources ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research has shown ... to reduce the frequency and level of relapse. , At the ... and Purpose,” will explore the critical tasks of the recovery phase and beyond ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Today, the Whole-Food ... announced that the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, ... Network. , Each week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... announce the addition of micro-needling services in their Napa Valley office. The technique ... of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of only ...
(Date:2/5/2016)... ... February 05, 2016 , ... The ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... again host, Swirl, A Wine Tasting Event at the La Gorce Country Club ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... SAN DIEGO , Feb. 5, 2016 Aethlon ... Jim Joyce , Chairman and CEO, will be presenting at ... New York, NY at 2:15 p.m. ... participate in an Immunotherapy Panel discussion taking place at 3:15 ... available for replay approximately one hour after the conclusion of ...
(Date:2/5/2016)... February 5, 2016 --> ... report states that the global active pharmaceuticals ingredients (APIs) ... predicted to reach US$185.9 bn by 2020. It is ... 2014 to 2020. The title of the report is ... by Geography, and by Therapeutic Area) - Global Industry ...
(Date:2/5/2016)... 5, 2016  Zimmer Biomet Holdings, Inc. (NYSE and ... announced underwritten secondary offering of 11,027,558 shares of its ... affiliates of Blackstone and Goldman Sachs.  The shares are ... of $96.45 per share. The selling stockholders will receive ... Biomet nor any of its directors, officers or other ...
Breaking Medicine Technology: